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Background: This retrospective study aimed to determine how often a perimetric examination 
should be carried out in order to identify visual field (VF) changes in patients with relatively 
early manifestation glaucoma.
Materials and methods: Patients included had a relatively recent manifestation of primary 
open-angle glaucoma. Patients with a minimum follow-up of 5 years and a minimum of seven 
VF tests were included. Statistical analysis was performed to verify the trend of variations in 
mean defect (MD) over time (PeriData). The results were subjected to a t-test for a comparative 
analysis of progression of VF changes over time. The annual rate of progression provided by 
PeriData considering all the VFs analyzed was compared with that obtained on half of the VF 
examinations during the same follow-up period. An analysis of the MD trend over time was 
also carried out in relationship to the number of VF tests done and by dividing the sample into 
a high-frequency group (more than eight VFs) and a low-frequency group (fewer than eight 
VFs) in the follow-up period.
Results: A total of 96 eyes of 96 patients were included, and overall 846 VFs were examined. 
The paired t-test performed comparing the MD index of all the VFs against half of them did not 
show statistical significance (P=0.537). The high-frequency group comprised 39 eyes (average 
VF 11.05±1.91, average time interval 0.76 years) while the low-frequency group comprised 
57 eyes (average VF 6.95±0.6, average time interval 1.21 years). The analysis of the MD trend 
in the high-frequency patients showed significance (P=0.017); the low-frequency group did not 
show statistical significance (P=0.08).
Conclusion: The number of VFs in a determined time interval was not significant. However, 
a greater frequency of tests provides a predictive evaluation of the rate of progression of early 
manifestation open-angle glaucoma.
Keywords: open-angle glaucoma, visual field, progression, ocular hypertension
Introduction
Glaucoma is a multifactorial neurodegenerative disorder characterized by progressive 
structural and functional injury of the optic nerve complex (optic nerve and parapapillary 
region).1–7 Evaluation of visual field (VF) damage remains the major index of the func-
tional impact of glaucoma, and the assessment of its progression has a direct effect on 
therapeutic decisions and the quality of life of patients.8–13 There is an ongoing debate 
on the number of VF tests and the time interval between tests, which are necessary 
in order to obtain a reliable progression trend. Based on theoretical considerations, it 
has been suggested that a large number of VF examinations are necessary to detect 
smaller yet clinically significant progression rates, especially in eyes demonstrating 
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a high degree of long-term fluctuation. It has also been sug-
gested, based on simulation data, that a minimum of three 
VF examinations in the first 2 years are required to achieve 
optimal sensitivity and specificity for detection of clinically 
significant rates of progression analysis.14 A reliable progres-
sion trend may help the ophthalmologist to assess treatment 
or schedule the frequency of follow-up visits. Indeed, not 
all patients need frequent VF testing, and only in a minority 
of patients does glaucoma progress fast enough to warrant 
frequent testing and aggressive therapy.15 The aim of our 
study was to determine the number of perimetric VF exami-
nations required to identify changes in the VF of patients in 
the first years of glaucoma, retrospectively. In particular, 
this was to establish if the number of tests carried out in an 
established time span influences the rate of progression and 
stage of disease. Therefore, we aimed to define the optimal 
number of examinations required over time in patients suf-
fering from glaucoma.
Materials and methods
This research was authorized by the Sapienza Ethics 
Commitee and followed the tenets of the Declaration of 
Helsinki. Informed consent was obtained from all subjects 
participating in the study.
Patients with a clinical diagnosis of recently manifest 
primary open-angle glaucoma (POAG) were selected. Inclu-
sion criteria were as follows: 1) Diagnosis of POAG less than 
2 years prior. Subjects were classified as having glaucoma if 
they had: a) intraocular pressure measured with Goldmann 
tonometry without therapy .22 mmHg; b) upon VF exami-
nation, at least 3 adjacent points reduced in sensitivity by 
5 dB, with one of the points being reduced by at least 10 dB; 
at least two adjacent points reduced in sensitivity by 10 dB 
or a difference of at least 10 dB across the nasal horizontal 
meridian at two adjacent points; none of the points should 
be edge points except immediately above or below the nasal 
horizontal meridian;16 c) an abnormal optic nerve head evalu-
ated by stereophotography by a glaucoma expert (AP). 2) 
Patients with a minimum follow-up of 5 years of VF tests 
(Octopus 1-2-3 program, G1 full-threshold strategy) and 
a minimum of seven VF tests performed during the study 
period. 3) Best-corrected visual acuity of at least 30/40 at the 
time of the first VF selected, and a refractive defect of ±8 D 
(spherical equivalent).
Exclusion criteria were patients with opacities of lens that 
were clearly evident at slit-lamp examination, and retinal or 
neurological diseases that could influence VF test results. 
Visual acuity assessment and a complete ophthalmological 
examination with slit lamp and indirect ophthalmoscopy were 
carried out at each VF-examination date.
Based on these criteria, a total of 96 patients (47 males 
and 49 females) were included in this study. The age range 
was 58–82 years (66±15.96 years). Only one eye per patient 
was selected. Two VF examinations were excluded before 
the first VF test was included, in order to improve the reli-
ability of the perimetric indices due to learning effects, 
present in any kind of perimetric technique.17–19 A VF test 
was considered reliable only when false-positive and false-
negative responses were less than 20% and fixation losses 
were less than 20%.20
For each eye considered, all the VFs were studied with 
statistical regression analysis in order to evaluate the rate 
of progression of mean defect (MD; dB/year) over time 
(PeriData for Windows version 2.3). The annual rate of 
progression of MD provided by PeriData on all the VFs was 
also compared with the data obtained by analyzing half of 
the VF tests. In particular, this was done by excluding one 
VF out of three (one VF was considered and the successive 
one not considered), in order to analyze only half of the VFs 
in the same follow-up period.
An analysis of the trend of the MD over time with 
PeriData was also carried out, dividing the sample into two 
groups in relation to the number of VF tests done in the aver-
age follow-up time for each eye. In this way, two different 
groups were created: the first was arbitrarily denominated 
the high-frequency group, with more than eight VFs exam-
ined, and the second was denominated the low-frequency 
group, with fewer than eight VFs examined in the follow-up 
period. The high-frequency group consisted of 39 eyes, 
with an average number of 11.05±1.91 VF tests per eye 
and average interval between tests of 0.76 years, while the 
low-frequency group consisted of 57 eyes, with an average 
number of 6.95±0.6 VF tests per eye and average interval 
between tests of 1.21 years.
statistical analysis
Paired t-tests were used to assess within-subject differences. 
Linear regression analysis was performed to assess the 
relationship between progression (dB/year) of the VF over 
time in both the high- and low-frequency groups. Intraclass 
correlation coefficients (ICCs) were used to determine the 
repeatability of measurements within groups. P-values 
less than 0.05 were considered statistically significant, and 
P,0.001 was considered to be highly statistically signifi-
cant. All calculations were carried out using SPSS software 
(version 20; IBM, Armonk, NY, USA).
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Results
Table 1 shows the baseline characteristics of the study cohort. 
An overall total of 846 VFs were examined from 1997 until 
2014. The average number of VFs for each eye examined was 
8.63±2.65. At baseline, the average MD was -4.08±4.03 dB. 
The rate of progression of MD of the all VFs examined 
(846) was -0.354 dB/year. The rate of progression of MD 
of half of the VFs examined (423) in the same time interval 
was -0.376 dB/year. Paired t-tests performed comparing the 
annual progression MD index of all the VFs vs MD index of 
half of the VFs (-0.376 dB/year) in the same time interval 
did not show any statistical significance (P=0.537).
Although no significant differences were found between 
all VFs (1-year progression rate) and half of the VFs, there 
were significant differences between the 3-and 6-month 
(P=0.003) and 1-year (P,0.001) progression rates (Figure 1). 
In addition, ICC analysis showed good agreement between 
the 1-year progression rate and half of the VFs progression 
rate (ICC 0.94, IC 95% confidence interval [CI] 0.9–0.96; 
P,0.001). Instead, no agreement was found between the 
3-month and 6-month progression rates vs the 1-year pro-
gression rate (ICC 0.05, 95% CI -0.42 to 0.39, P=0.40 and 
ICC -0.17, 95% CI -0.93 to 0.46, P=0.52, respectively).
The MD-trend analysis carried out with PeriData on the 
high-frequency group showed significance (-0.362 dB/year, 
P=0.017), while in the low-frequency group the MD-trend 
analysis did not show any statistical significance (-0.357 dB, 
P=0.080). Linear regression analysis showed no relation-
ship between the low-frequency group and follow-up in 
time (r2=0.002, P=0.48), whereas a significant relation-
ship was found in the high-frequency group (r2=0.024, 
P,0.001) (Figure 2).
Discussion
Our results suggested that in a period of 7 years, the total 
sum of VF tests did not significantly influence the long-term 
rate of progression of MD in recently manifest POAG. 
However, a higher frequency of VF testing, as in the high-
frequency group led to earlier detection of glaucoma progres-
sion, especially with global trend analyses, demonstrating 
a better capacity of evidencing VF worsening than in the 
low-frequency group.
The evaluation of the variations of perimetric indices 
obtained by statistical analysis currently represents a valid 
tool in the evaluation of the progression of VF damage. An 
estimate of the rate of progression of VF damage is essential, 
as it enables the rapid identification of patients who present 
worsening, which indicates a higher risk toward visual dis-
ability. Evaluation can be focused on specific perimetric varia-
tions over time (event analyses) or it can be a global perimetric 
evaluation (trend analyses).21 In the event-based method, the 
difference in perimetric sensitivity of a test is determined with 
comparison of previous VFs taken as baseline tests. 
The analysis of the trend of sensitivity of all VFs analyzed 
in follow-up is evaluated using linear regression to determine 
the presence of points of worsening that are statistically 
significant. The advantage of trend analysis is that a linear 
change can give an estimate of the progression over time. 
There are still numerous doubts on the most appropriate type 
of analysis, and the frequency and number of examinations 
necessary to determine a clinically significant perimetric 
variation, which can be predictive of VF deterioration over 
time.22 The absence of general consensus on the criteria to 
identify significant changes in VF over time is shown by the 
variability in the criteria used in various trials, such as the 
NTGS,23 AGIS,24 and EMGT.25
The ability to predict the future course of progres-
sion based on precedent VFs has an important role in the 
Table 1 Baseline characteristics of the study cohort
Variables Values
eyes, n 96
age at baseline 58±15.96 years
sex
Male, n 47
Female, n 49
Mean follow-up time 6.4±1.64 years
Mean visual fields tested 8.63±2.65
Baseline visual field, MD -4.08±5.28
Mean time of diagnosis of POAG in first visual field 1.52±0.45 years
Total sum of visual fields examined 846
Note: Values expressed as mean ± standard deviation.
Abbreviations: MD, mean defect; POAG, primary open-angle glaucoma.
???
?
???
?
???
?
???? ???? ???????? ????????
???
???
????
????
?????
???
????
Figure 1 Progression rate of mean defect in all visual field over 1 year (year), in the 
same follow-up period considering one VF out of three (half) and in the first 3 and 
6 months of follow-up (3 month; 6 month).
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management of glaucoma, especially in cases that worsen. 
Nouri-Mahdavi et al26 studied a subgroup of 161 patients in 
the AGIS study in order to evaluate perimetric progression 
over 8 years of follow-up. Multivariate analysis of some 
risk factors evaluated over 4 years showed that the major 
predictive factor of VF deterioration was a negative index, 
establishing that patients with higher deterioration were 
those who showed worsening in the first 4 years. Therefore, 
the authors concluded that close follow-up is critical in the 
initial stages of diseases in order to determine the successive 
trend of the pathology, and that it is fundamental to perform 
a higher number of VF tests in the first stages of disease in 
order to determine early worsening.26
The last edition of the European Glaucoma Society 
guidelines suggests that all newly diagnosed patients should 
be tested with standard automated perimetry three times per 
year during the first 2 years following diagnosis.27
Other authors reported that a frequency of testing above 
four tests per year did not add relevant information regard-
ing VF alterations studied with point-wise linear regression. 
Furthermore, they found that frequent testing, especially in 
patients with a low index of progression, could potentially 
increase the number of false positives and reduce the speci-
ficity of the test.28
Our data are in agreement with reports that suggest that 
in recently manifest glaucoma, in order to have an estimate 
index of linear regression of VF decay, a high number of 
tests is necessary in the first stages of follow-up, and that 
the capacity of evidencing VF worsening based on only one 
test per year is extremely low. Our results showed that in a 
follow-up period of 7 years, the global number of VF tests 
was not fundamental to determine the entity and the index of 
progression over time. Indeed, both the t-test relative to the 
annual index of progression and linear regression of global 
MD were not significant. However, the significance relative to 
MD linear regression eyes with more than eight VF tests over 
the follow-up period (average 11.05±1.91 VFs) was different. 
Our study was focused on eyes with a recent manifestation of 
POAG, and showed that a higher number of VF tests, espe-
cially in the first stages of disease, allowed earlier detection 
of VF deterioration, allowing appropriate therapeutic man-
agement and avoiding a negative influence on the quality of 
life of patients. It must be emphasized that in the absence of 
statistical significance of both the t-test, performed on half 
of the global VFs without considering the interval between 
tests, and linear regression analysis in patients who had 
undergone fewer than eight VF tests in 7 years confirms that 
a higher frequency of tests in the initial stages of disease is 
fundamental toward clinical predictability and the follow-up 
of glaucoma. Our results have significant health care policy 
implications with regard to determining the frequency of VF 
testing in patients with glaucoma. The retrospective approach 
of this study represents its strongest limitation.
Disclosure
The authors report no conflicts of interest in this work.
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